title: Gestational trophoblastic neoplasia: an update.
abstract: Gestational trophoblastic neoplasia (GTN) includes invasive mole, choriocarcinoma, and placental site trophoblastic tumors. The overall cure rate in treating these tumors currently exceeds 90%. Thorough evaluation and staging allow selection of appropriate therapy that maximizes chances for cure while minimizing toxicity. Nonmetastatic (stage I) and low-risk metastatic (stages II and III, World Health Organization score < 7) GTN can be treated with single-agent chemotherapy, resulting in a survival rate approaching 100%. High-risk metastatic GTN (stage IV, WHO score > or = 7) requires initial multiagent chemotherapy with or without adjuvant radiation and surgery to achieve a survival rate of 80% to 90%.
authors.affiliation: John I. Brewer Trophoblastic Disease Center, Northwestern University Feinberg School of Medicine, 250 East Superior Street, Suite 05-2168, Chicago, IL 60611, USA.
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Morgan
authors.forename: John R
authors.initials: JR
authors.lastname: Lurain
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D006063:Chorionic Gonadotropin / Q000378:metabolism; D015195:Drug Design; D005260:Female; D005500:Follow-Up Studies; D031901:Gestational Trophoblastic Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D009362:Neoplasm Metastasis; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic; D012306:Risk; D014328:Trophoblastic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D006063:Chorionic Gonadotropin